{"id":21601,"date":"2024-07-01T15:53:28","date_gmt":"2024-07-01T15:53:28","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21601"},"modified":"2024-07-02T12:44:45","modified_gmt":"2024-07-02T12:44:45","slug":"vetter-expands-global-manufacturing-capacity-for-injectable-therapeutics","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/vetter-expands-global-manufacturing-capacity-for-injectable-therapeutics\/","title":{"rendered":"Vetter expands global manufacturing capacity for injectable therapeutics"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

\r\n\r\n\"\"<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\n

Vetter expands global manufacturing capacity for injectable therapeutics<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Leading contract development and manufacturing organisation (CDMO) Vetter has announced significant expansion plans in both the United States and Germany, aiming to meet the growing demand for outsourced development and manufacturing of injectable medications.<\/h3>\n

<\/p>\n

Doubling clinical manufacturing capacity in the US<\/h4>\n

Vetter plans to relocate and expand its Development Services site from Skokie, Illinois, to Des Plaines. This move will effectively double the capacity of Vetter Development Services in the US, with new facilities for clinical manufacturing and related services. The expansion is driven by increasing customer needs at both the current Skokie site and the company\u2019s clinical manufacturing site in Rankweil, Austria.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

New commercial production site in Germany<\/h4>\n

In response to the recently approved \u2018German Pharmaceutical Strategy\u2019 and increased investments by pharmaceutical companies in Germany, Vetter has received approval to establish an additional commercial production site in Saarlouis, Saarland. The company plans to develop a 125-acre site in phases, with pharmaceutical production expected to commence by 2030. This expansion is projected to create up to 2,000 new local jobs.<\/p>\n

Thomas Otto, Managing Director of Vetter, explained the decision: \u201cAfter careful consideration, Germany, and Saarland in particular, prove to be the location with the best-fitting conditions for expanding our commercial operations. In addition to the existing and growing competencies and capacities at and around our sites in Ravensburg, we will be able to further expand our range of services.\u201d<\/p>\n

Strategic response to market trends<\/h4>\n

The expansion plans come as the injectable therapeutics industry experiences a rise in outsourcing of development, manufacturing, assembly and packaging needs to CDMOs. Vetter\u2019s investments aim to address the long-term capacity requirements of both clinical and commercial customers.<\/p>\n

Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family, said: \u201cAs an independent and family-owned company, we prioritize thoughtful and strategic planning to support our long-term business growth. With these investments we reaffirm our commitment on both continents and enable that Vetter Pharma will continue to be part of a growing market in the future.\u201d<\/p>\n

Enhancing capabilities for complex injectables<\/h4>\n

These expansions form part of Vetter\u2019s comprehensive strategy to position itself for future growth in drug product development, aseptic injectable filling, device assembly and packaging. The company aims to increase its capacity for handling complex injectables, contributing to the global supply of life-saving medications.<\/p>\n<\/div><\/section>
\n